This federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $3,984,239.00 to Microvascular Therapeutics Inc. to conduct IND-enabling studies for targeted phase shift microbubbles for sonothrombolysis. The funding supports research and development activities by the for-profit biotechnology company to advance ultrasound contrast agent and delivery system technologies for diagnostic and therapeutic biomedical applications, with a focus on cardiovascular, cancer, and neurological disorders. Key project activities include formulation of ligand-targeted and acoustically-active nanoparticles, evaluation of binding selectivity and drug delivery capabilities, and testing of thrombus disruption and tumor ablation efficacy in animal models. This work aims to translate the company's microbubble and nanodroplet platforms for clinical use, leveraging its expertise and partnerships developed through prior federal grant funding from agencies like the NIH, DoD, and NSF.